Landos Biopharma, a Phase 2 biotech developing oral small molecule therapies for autoimmune diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. The company leverages its proprietary AI-based precision medicine LANCE platform to id
source https://www.nasdaq.com/articles/autoimmune-biotech-landos-biopharma-files-for-a-%24100-million-ipo-2021-01-13